5,419 Shares in GSK plc (NYSE:GSK) Bought by Carnegie Capital Asset Management LLC

Carnegie Capital Asset Management LLC purchased a new stake in shares of GSK plc (NYSE:GSK) in the fourth quarter, HoldingsChannel.com reports. The firm purchased 5,419 shares of the pharmaceutical company’s stock, valued at approximately $201,000.

Other institutional investors have also recently added to or reduced their stakes in the company. FMR LLC grew its holdings in shares of GSK by 7.7% during the 3rd quarter. FMR LLC now owns 18,099,513 shares of the pharmaceutical company’s stock worth $656,107,000 after purchasing an additional 1,291,161 shares during the period. Price T Rowe Associates Inc. MD grew its stake in GSK by 5.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 12,292,913 shares of the pharmaceutical company’s stock worth $437,383,000 after buying an additional 673,419 shares during the period. Primecap Management Co. CA increased its position in shares of GSK by 2.4% in the third quarter. Primecap Management Co. CA now owns 12,058,770 shares of the pharmaceutical company’s stock worth $437,130,000 after acquiring an additional 287,000 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its stake in shares of GSK by 32.5% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 9,621,370 shares of the pharmaceutical company’s stock valued at $419,107,000 after acquiring an additional 2,362,274 shares during the period. Finally, Royal Bank of Canada lifted its holdings in shares of GSK by 5.1% during the 3rd quarter. Royal Bank of Canada now owns 8,079,897 shares of the pharmaceutical company’s stock valued at $292,896,000 after acquiring an additional 389,871 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Stock Down 0.9 %

Shares of NYSE GSK opened at $39.60 on Thursday. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.62 and a current ratio of 0.88. GSK plc has a 1 year low of $33.33 and a 1 year high of $43.84. The stock’s 50-day simple moving average is $41.99 and its 200-day simple moving average is $38.76. The firm has a market cap of $82.07 billion, a price-to-earnings ratio of 13.16, a PEG ratio of 1.83 and a beta of 0.64.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.04). GSK had a net margin of 16.24% and a return on equity of 51.45%. The business had revenue of $10 billion for the quarter, compared to analyst estimates of $9.79 billion. As a group, equities analysts anticipate that GSK plc will post 4.02 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, April 11th. Investors of record on Friday, February 23rd were paid a $0.3564 dividend. This represents a $1.43 dividend on an annualized basis and a dividend yield of 3.60%. The ex-dividend date was Thursday, February 22nd. This is a positive change from GSK’s previous quarterly dividend of $0.34. GSK’s payout ratio is 52.82%.

Wall Street Analyst Weigh In

Several research firms have commented on GSK. Morgan Stanley started coverage on GSK in a research report on Tuesday, January 23rd. They issued an “equal weight” rating on the stock. Citigroup upgraded GSK from a “neutral” rating to a “buy” rating in a report on Tuesday, February 13th. Guggenheim raised GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. Finally, Jefferies Financial Group upgraded shares of GSK from a “hold” rating to a “buy” rating in a research note on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy”.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.